Trafermin
Medication
From Wikipedia, the free encyclopedia
Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.[2][3][1] It is also currently in preregistration for the treatment of periodontitis.[2][4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.[5][6] The drug has been marketed in Japan since June 2001.[citation needed]
Trade namesFiblast
Other namesCAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)
| Clinical data | |
|---|---|
| Trade names | Fiblast |
| Other names | CAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced) |
| Routes of administration | Topical (spray)[1] |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C764H1201N217O219S6 |
| Molar mass | 17122.67 g·mol−1 |
